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Cellular Origin of Cancer:
Dedifferentiation or Stem Cell Maturation
Arrest?
by Stewart Sell
Given the fundamental principle that cancer must arise from a cell that has the potential to
divide, two major nonexclusive hypotheses of the cellular origin of cancer are that malignancy
arises a) from stem cells due to maturation arrest or b) from dedifferentiation of mature cells
that retain the ability to proliferate. The role of stem cells in carcinogenesis is clearly demon-
strated in teratocarcinomas. The malignant stem cells of teratocarcinomas are derived from
normal multipotent stem cells and have the potential to differentiate into normal benign
mature tissue. A widely studied model supporting dedifferentiation has been the putative ori-
gin of hepatocarcinomas from "premalignant" foci and nodules induced in the rat liver by
chemicals. However, the dedifferentiation concept for hepatocarcinogenesis is challenged by
more recent interpretations indicating that hepatocellular carcinoma arises from maturation
arrest caused by abherrant differentiation of determined stem cells. Either hypothesis is sup-
ported by the cellular changes that occur in the rodent liver after different hepatocarcinogenic
regimens. The formation of foci and nodules from altered hepatocytes supports dedifferentia-
tion; the proliferation of small oval cells with the potential to differentiate into either biliary
ducts or hepatocytes supports arrested maturation of determined stem cells. It is now postulat-
ed that foci and nodular change reflect adaptive changes to the toxic effects ofcarcinogens and
not "preneoplastic" stages to cancer. The stem cell model predicts that genotoxic chemicals
induce mutations in the determined stem cell which may be expressed in its progeny.
Proliferation of initiated cells is induced by promoting events which also allow additional
mutations to occur.
Introduction
Although analysis of carcinogenic events by modern
techniques ofmolecular oncology has greatly increased
our understanding of how malignant transformation
may occur, there are still basic questions concerning
the cellular process from which cancer arises. Given
the fundamental principle that cancer cannot arise in
terminally differentiated cells but must arise from a
cell that has the potential to divide, there are two pos-
sibilities: tumors arise from dedifferentiation of
mature cells or from maturation arrest of immature
stem cells.
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Embryonal Theory ofCancer
The "stem cell" or embryonal origin of cancer may
have been the first generally accepted theory of the
etiology of cancer (1). The embryonal rest theory of
cancer has been attributed to Cohnheim (2). He pro-
posed that cancers arose from displacement of embry-
onic cells. At some stage of embryonic life, cells
become isolated or fixed while they still possess great
energy. These cells normally become differentiated in
the adult, but because of their isolation they manifest
embryonic capacity for continued growth in the adult.
Rippert (3) expanded the embryonic rest theory to
include the possibility that cells expressing embryonic
potential for growth could arise in the adult (dediffer-
entiation). However, Rotter (4) proposed that primi-
tive sex cells might lodge anywhere outside the ulti-
mate sex glands during development and serve as the
origin of tumors. He also thought that the growth of
epithelial tumors depended on primary changes in the
underlying connective tissue, which allowed invasion
and expansive growth ofepithelium.S. SELL
With the identification of cell-free filtrates (5) and
exogenous chemicals (6) that could cause cancer, the
idea that an infectious event caused dedifferentiation
of mature cells to form cancers became more popular.
The more recently developed concept of infection with
oncogenic viruses or of activation of proto-oncogenes
(7,8) as the causative events in cancer has been
explained by action of oncogene products on adult cells
causing transformation to malignant phenotype (dedif-
ferentiation). This explanation is supported by the
observation that transfection or activation of onco-
genes can cause proliferative changes in apparently
mature cells in tissue culture. However, the process of
carcinogenesis in vivo includes proliferation ofless dif-
ferentiated cells, and cell lines in culture always con-
tain a certain fraction of proliferating cells that may
represent determined stem cells.
Stem Cell Tumors
The similarity of histologic appearance and growth
characteristics between embryonic tissues and cancer
is a major observation that supports the concept of a
stem cell origin of cancer. In particular, the character-
istics of teratocarcinomas, which produce a variety of
undifferentiated as well as fully differentiated cells,
are more consistent with a stem cell origin than dedif-
ferentiation (9). Teratocarcinomas contain structures
resembling presomite embryos (embryoid bodies)
intermixed with virtually every recognizable fetal and
adult tissue (10, 11). Pierce et al. (12) showed that tera-
tocarcinomas (embryonal carcinomas) not only con-
tained malignant presomatic cells, but also included
benign somatic tissue. In addition, the ability of trans-
plantable teratocarcinomas ofmice to differentiate into
mature benign cells provides irrefutable evidence for
the stem cell origin ofthis form of cancer (13).
Transplantable teratocarcinomas were first pro-
duced by Stevens (14) by injecting the cells from the
genital ridge of F1 mice into the testicles of parental
mice. The normal genital-ridge cells grew in the testes
and gave rise to solid teratocarcinomas that have now
been passed for over 200 generations in inbred
parental mice (Fig. 1). When growing in the recipient
mouse, proliferating, malignant, transplantable terato-
carcinoma cells differentiate into benign cells located
in well-differentiated keratin pearls within the tumor
(16). Transplantation ofthe tumor-producing core cells
of malignant teratocarcinomas into normal blastocysts
may result in birth of normal differentiated adult cells
(17-19). Labeled embryonal-carcinomal cells localize
preferentially in the mural trophectoderm of the blas-
tocyst, in the primitive endoderm, and rarely in the
inner cell mass. The carcinoma cells differentiate into
differentiated cells in accordance with their localization
(20). Thus, at least for this form of cancer, the malig-
nant potential exists in the stem cell and may be con-
trolled by environmental factors present in differenti-
ating tissue.
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FIGURE 1. Origin ofmalignant teratocarcinomas from normal germi-
nal cells and development of normal organs from transplantable
teratocarcinoma cells. Malignant teratocarcinomas were derived
by injection of normal genital-ridge cells of F1 mice into the testi-
cles of parental-strain mice. These teratocarcinomas have been
maintained for over 200 generations by transplantation and may
be grown in tissue culture. The malignant undifferentiated stem
cells ofthe tumor (embryoid bodies) may be transformed into nor-
mal tissue after insertion into normal blastocysts of a different
mouse strain and viable mosaic mice obtained. These mosaic mice
have organs containing tumor-derived cells, as well as cells ofthe
blastocyst, as determined by H2 tissue type, red blood cell type,
immunoglobulin allotypes, and isozymes from Sell (15).
Maturation Arrest/Blocked Ontogeny
The concept of blocked ontogeny, attributed to
Potter (21), is a postulate ofthe stem cell model of car-
cinogenesis and cell renewal as adumbrated by Pierce
et al. (13) In Figure 2, the undifferentiated stem cell is
represented at the left. During organogenesis, stem
cells differentiate to produce tissue stem cells. Stem
cells that are committed to form a certain tissue are
called "determined." The determined stem cells are the
cells that are available to proliferate to form a given
organ or cell lineage. The determined stem cells give
rise to progeny that begin to accumulate the molecules
ofspecialized cell types in their cytoplasm. During nor-
mal cell renewal the determined stem cell divides to
produce two daughter cells. One daughter cell remains
as a stem cell; the other daughter cell expresses a more
differentiated state. These differentiating cells are
capable of additional rounds ofproliferation, eventual-
ly giving rise to terminally differentiated cells. Note
that in Pierce's model the existence of a determined
liver stem cell is highlighted by a question mark, and
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FIGURE 2. Model ofcell renewal and carcinogenesis. The stem cell is
depicted on the left with progressive differentiation to terminally
differentiated cells at the right (post-mitotic). Expression of the
malignant phenotype could occur at any stage ofdifferentiation of
mitotically active cells. Initiation may take place at the level ofthe
stem cell, but tumors may appear to arise from more differentiat-
ed cells when additional mutations have occurred that permit
expression of the malignant phenotype. The top lineage would
hold for rapidly renewing populations of cells, such as the gas-
trointestinal tract, skin, and hematopoietic tissue. The second lin-
eage represents tissues that normally turn over slowly, such as
the liver. The question marks for the liver indicate that previously
the ability of adult liver cells to proliferate and replace destroyed
liver cells led investigators to conclude that there were neither
stem cell nor terminally differentiated cells in the liver. However,
more recent studies indicate not only that normal liver cell
turnover involves periportal stem cells, but also that mature liver
cells in the central zone are terminally differentiated. The bottom
lineage depicts nerve cells of the adult, which are terminally dif-
ferentiated, do not proliferate, and do not give rise to tumors.
Modified from Pierce et al. (13).
the presence of a terminally differentiated liver cell is
also highlighted by a question mark. In this article the
nature ofthe determined stem cell for the liver will be
presented, as well as evidence that there are terminal-
ly differentiated liver cells.
Is There a Liver Stem Cell?
The question of whether there is a liver stem cell
was posed in a recent review (22). The concept of the
liver stem cell and its role in chemical hepatocarcino-
genesis has developed from a number of studies of the
cellular lineage of chemically induced hepatocellular
cancer (23-29). There are two possible cellular lineages
of cancer during chemical hepatocarcinogenesis (Fig.
3): tumors may arise by dedifferentiation ofadult hepa-
tocytes or by maturation arrest of stem cells. The
sequence offoci to nodules to cancer and the associated
changes in the enzyme content of nodular and carcino-
ma cells imply dedifferentiation of mature hepatocytes
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FIGURE 3. Possible cellular pathways to liver cancer. Two cellular
lineages to liver cancer are presented: (I) dedifferentiation of
mature hepatocytes and (II) aberrant differentiation ofstem cells.
The classic interpretation of the effect of chemical carcinogens in
producing so-called premalignant foci and nodules implies dedif-
ferentiation. The induction of proliferation of oval cells by chemi-
cal hepatocarcinogens is more consistent with derivation from
stem cell maturation arrest (blocked ontogeny).
(30-36). However, an origin from stem cells is support-
ed by the proliferation of small bile-ductlike cells that
arise at the portal zone, proliferate extensively, and
migrate between the hepatic cords to the central zone
(37-41). These small bile-ductlike cells are called oval
cells (39, 41; see Table 1). Oval cells contain markers
such as a-fetoprotein (AFP). (43-47, 53) and epitopes
identified by monoclonal antibodies (53-56), which are
also found in hepatocellular carcinomas (HCC) that
appear much later. Oval cells may differentiate into
normal duct cells or hepatocytes (41, 56, 58) or migrate
into persistent nodules where they may give rise to
HCC (55, 57). The relationship of oval cells to the foci
and nodules that develop during chemical hepatocar-
cinogensis was examined using four different models.
Carcinogen-Induced Oval Cell
Proliferation
The effects of five carcinogenic regimens that show
different kinetics of oval cell production, foci and nod-
ule formation, and serum AFP elevations are com-
pared in Table 2 and Figure 4. AFP is a serum protein
found at high levels in fetal serum that becomes re-ele-
vated in adults after liver proliferation or development
of HCC (20,59,60). In our studies serum AFP levels
were used to determine liver cell or oval cell prolifera-
tion early after carcinogen exposure, mitogen treat-
ment (including partial hepatectomy), and necrotic
liver injury, as well as development ofliver cell cancer
later after carcinogen treatment (Fig. 5). In recombi-
nant, inbred mice, serum AFP may be used to predict
which animals develop adenomas or HCC and to select
animals for morphologic examination (61,62). Our first
study used the cyclic AAF feeding regimen of Teebor
and Becker (63). Although it was anticipated that AFP
would be found in foci and nodules during the early ele-
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Table 1.
Short history ofoval cells and a-fetoprotein (AFP).
1944-Opie describes small cells in the liver after exposure ofrats
to butter yellow (37).
1954-Price et al. note similar cells after 3'methyl-4-dimethyl-
aminoazobenzene exposure (38).
1956-Farber coins the term "oval cells" for the small cells (39)
1957-Popper concludes that oval cells arise from bile duct cells
(40).
1964-Grisham and Porta conclude that oval cells may differenti-
ate into bile duct cells or mesenchymal cells (41).
1964-Ruben, using autoradiography, concludes that oval cells can
differentiate into hepatocytes (42).
1973-75-Onoe and coworkers localize AFP to oval cells early dur-
ing hepatocarcinogensis (43,44).
1977-78-Tchipysheva et al. (45), Kuhlmann (46), and Sell (47),
report AFP is not in foci or nodules.
1978-Shinozuka et al. report massive proliferation ofoval cells in
rats fed carcinogens in choline-deficient diets (48,49).
1980-82-Sell et al. propose oval cells as precursor cells for hepa-
tocellular carcinomas and culture oval cells in vitro (23,24,50).
1984-Sell and Salman identify proliferating periportal cells early
after carcinogen exposure with later ductal cell proliferation and
suggest that this may be the stem cell for hepatocellular carcino-
ma (51).
1985-Yaswen et al. note increased expression of protooncogenes
(c-myc and c-K-ras) in oval cells when compared to normal liver
(52).
1989-Dunsford et al., using monoclonal antibodies, conclude that
oval cells represent proliferation and differentiation of a liver
stem cell and that foci and nodules are adaptive changes and not
precursors to hepatocellular cancer (55,56).
1990-Sell proposes that liver stem cell may be either periportal
cell ortransition duct cell (21).
vation of serum AFP, it became clear that serum AFP
became elevated before nodules appeared and that the
cells containing AFP were oval cells and not foci or
nodules (43-47). From these observations it was tenta-
tively concluded that HCC might not arise from foci
and nodules but from oval cells (Fig. 6).
A study ofthe early cellular events with dimethylni-
trosamine (DEN) was most revealing regarding the
cellular lineage of HCC (56). This model was chosen
because there was little recognizable early oval-cell
REGIMEN CELLULAR CHANGES
loll I .\,on IN LIV
CYCLIC AAF OVAL CELLS->FOCI->NODULES->CANCER
DEN OVAL CELLS->MICROCARCINOMAS->CANCER
SERUM AFP
CD-AAF OVAL CELLS->FOCI->NODULES->CANCER
SOLT-FARBER
WY-14643 MITOSIS->NORMAL->FOCI->CANCER
FIGURE 4. Cellular changes in the liver and kinetics of serum aX-
fetoprotein (AFP) elevations in rates exposed to different carcino-
genic regimens (see text and Table 2). In the cyclic a-acetylamino-
fluorene (AAF), CD-AAF, and Solt-Farber models, early AFP
elevation is associated with oval-cell proliferation and late AAF
elevation with tumor development. The cellular changes and
serum AFP elevation seen with the CD-AAF and Solt-Farber
models are similar, except that the massive oval-cell proliferation
and serum AFP elevation is delayed in the Solt-Farber model
until AAF feeding stops. Dimethylnitrosamine produces little
oval-cell proliferation early, but oval cells and transition cells
between oval cells and atypical hepatocytes can be seen using
monoclonal antibodies OV6 and T6 (55). WY-14643, a nongenotox-
ic peroxisome proliferator, induces liver cell proliferation (mitoge-
nesis) and a small associated AFP elevation, but subsequent ele-
vation ofAFP has not been reported.
change and no early elevation of serum AFP, a marker
associated with early oval-cell proliferation during car-
cinogen exposure (60). In this model, HCCs appear to
arise from microscopic foci of atypical hyperplasia,
rather than from either oval cells or preneoplastic nod-
ules seen in other models. However, when monoclonal
antibodies were applied to identify different cell popu-
lations, the early appearance of oval cells was readily
detected (OV6+), and morphologic evidence of trans-
formation of oval cells to larger cells bearing the HCC
phenotype (T6) was seen (56).
Oval cells were also identified as the AFP-containing
cells in the Solt-Farber model of inducing HCC. This
Table 2.
Oval cell proliferation and a-fetoprotein production in selected models ofhepatocarcinogenesis in rats.
Preneoplastic morphologic change Serum AFP levels
Carcinogen Early Late Early Late Hepatomas
Cyclic AFF Increasing oc, foci Nodules, OC, ducts ++ + +++/0
DEN Little change OC, microcarcinomas 0 ++ ++++
CD-AAF Massive OC Foci, nodules +++ ++ +++
DEN-AAF-PHa Massive OC, foci Nodules +++ ++ +++/+
WY-14643 Hepatocyte Mitosis Microcarcinomas + 0 0
Abbreviations: AFP, a-fetoprotein; AAF, N-2-fluorenylacetamide; OC, oval cells; DEN, diethylnitrosamine; CD, choline deficiency;
PH, partial hepatectomy; WY, Wyeth.
aSolt-Farber model.
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FIGURE 5. Serum a-fetoprotein (AFP) levels in rats. Elevated serum concentrations in mice and rats are found with events that induce normal
or abnormal liver cell proliferation, such as development of the fetal liver, restitutive liver injury after partial hepatectomy or chemical
injury, mitogen exposure (phenobarbital, peroxisome proliferators), exposure to chemical hepatocarcinogens, and growth of hepatocellular
carcinomas. From Sell and Becker (60).
regimen was designed to produce rapid development
offoci, nodules, and cancer (65). Cells are initiated by a
nonnecrotic injection of DEN, followed by a 2-week
feeding ofAAF, with a partial hepatectomy performed
after 1 week of AAF feeding. The AAF is given to
inhibit proliferation of the noninitiated hepatocytes
that would be stimulated by the partial hepatectomy
(PH), thus allowing the growth stimulus of the PH to
act on the DEN-initiated cells. However, this regimen
not only induces foci and nodule formation, but also
there is massive, early oval-cell proliferation. Later,
cells with oval cell phenotypes may be seen within per-
sisting nodules. This is interpreted to indicate that
even when HCC arises within a nodule, it may have
originated from the oval cell lineage (56,58).
The fourth regimen, feeding a choline-deficient diet
containing AAF (CD-AAF), was chosen to identify the
earliest proliferating cells after hepatocarcinogen
exposure. This regimen induces HCC rapidly com-
pared to other regimens and produces massive, early
oval-cell proliferation associated with elevated serum
AFP concentrations (66). Using autoradiography, it
was found that the first cells to proliferate were locat-
ed in the periportal zone, next to the bile ducts (50).
After 3 days, labeling of bile duct cells was seen, and
later many bile duct cells were labeled. The proliferat-
ing cells expanded across the hepatic acinus from the
portal triad to the central vein within 1 month. Differ-
entiation into both bile duct cells and small hepatocyte
cells was apparent after 2-3 weeks. Thus, in these four
different models of chemical hepatocarcinogenesis,
selected because of different cellular changes preced-
ing liver cancer, evidence for the development of can-
cers from oval cells in the liver was obtained (27).
WY-14643 stimulates peroxisome proliferation and is
a nongenotoxic mitogen (67,68) that induces short-
term proliferation ofliver cells and elevations of serum
AFP early after administration (69), followed by a
prolonged period oflittle change in the liver. With pro-
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Figure 6. Morphologic changes and serum a-fetoprotein (AFP) lev-
els during cyclic feeding of a-acetylaminofluorene (AAF). After
four 2-weeks-on/1-week-off cycles of feeding AAF (a total of 12
weeks), rats develop one or sometimes two hepatocellular carcino-
mas 24 weeks later. After each AAF feeding the livers ofthe rats
contain a progression oflesions from small foci ofbasophilic hepa-
tocytes to larger eosinophilic foci to nodules ofincreasing size that
distort the liver. If the fourth cycle is not fed, all of the changes
are reversible, However, after the fourth cycle most of the nod-
ules still disappear ("remold"), but hepatocellular carcinoma
(HCC) develops 24 weeks later from what appear to be persistent
nodules that do not regress (64). The progressive histologic and
enzymatic changes in the foci and nodules preceding the appear-
ance of HCC led a number of investigators to conclude that foci
represent initiated hepatocytes that may be selected by further
treatment to express the malignant phenotype (32-36). However,
there is also early proliferation of oval cells, which differentiate
into normal liver and bile duct cells as well as migrate into nodules
and transform into hepatocellular carcinomas. Elevations of
serum AFP are associated closely with oval-cell proliferation and
tumordevelopment, but not with noduleformation.
longed administration, enzyme-altered foci appear (70)
that are different from those induced by genotoxic
chemicals that they do not contain increased carcino-
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gen-detoxifying enzymes (71,72). Later, AFP-negative
cancers are seen (69). Oval-cell proliferation has not
been clearly defined using AFP or monoclonal anti-
body markers in this model, and the cellular precur-
sors to cancer may be different from those of other
regimens.
Where Is the Liver Stem Cell?
If there is a liver stem cell, where is this cell in the
normal liver and what is its relationship to the oval
cells seen duringtreatment with chemical carcinogens?
Three candidates are the terminal duct cell (40,41) the
transition duct cell (22), or a periportal stem cell (51).
The relationships of these cell types is illustrated in
Figure 7. Earlier autoradiographic studies implicated
terminal bile duct cells as the precursors of oval cells
(40,41). However, the conclusion that oval cells come
from duct cells was based on autoradiographic studies
done several weeks after carcinogen exposure (41,74).
Using autoradiography during the first 3 days after
CD-AAP, the majority ofthe proliferating-cell popula-
tion was identified as a periportal cell, whereas after 3
days, labelling increased in the duct cell population
(50). These early labeled cells were identified by elec-
tron microscopy as small periportal cells, and later
duct cells, in particular, transition duct cells (22,51).
HEPATOCYTES TRANSITION
Later, when oval-cell proliferation is at a peak, many
of the oval cells infiltrating the liver cords are transi-
tion duct cells (41). It is possible that both the transi-
tion duct cell and a periportal-liver-determined stem
cell have the potential to proliferate and differentiate
into duct or liver cells. Which cell is predominant may
depend on the degree ofcarcinogen stimulation or liver
cell injury. The greater the stimulus, the more likely it
is to involve the less differentiated periportal cell.
Bile Duct Proliferation
An argument against the terminal bile duct as the
liver stem cell is that stimulation ofbile duct prolifera-
tion per se does not result in hepatocarcinogenesis
(42). Agents that selectively stimulate bile duct prolif-
eration do not induce oval-cell proliferation. Induction
of bile duct hyperplasia by nonhepatocarcinogens such
as bile duct ligation, 4,4'-diaminodiphenylmethane
(DDPM), or a-naphthylisothiocyanate (ANIT) do not
induce AFP or albumin-containing duct cells (75-77).
There is one report identifying AFP-containing bile
duct cells after ANIT (78), but this was not found in
our studies (75,76). Elmore and Sirica (79) have demon-
strated that ductular cells may be stimulated to prolif-
erate and differentiate into cells expressing mucin
(intestinal metaplasia) or cells resembling hepatocytes
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FIGURE 7. Normal and neoplastic stages ofdifferentiation in the liver. This figure depicts the architecture ofthejunction between hepatocytes
and bile ducts including the three cell types that have been implicated as giving rise to hepatocellular carcinomas: the terminal duct cells,
transition duct cells, and the putative periportal liver stem cell. Transition duct cells have tightjunctions with hepatocytes on one side and
bile duct cells on the other (73). The thick arrows indicate the putative stages ofrestitutive cell renewal from periportal stem cells to transi-
tion duct cells to liver cells on one side and bile duct cells on the other. The thin arrows depict neoplastic proliferation. After exposure to
hepatocarcinogens, many oval cells have extensive plasma membrane appositions between hepatocytes and bile-ductlike cells, including
desmosome structures, tight junctions, and microvilli interdigitations (74). During cenogenesis, it is postulated that hepatocellular carcino-
mas arise from eitherthe putative periportal stem cells or from the transition duct cells, ortheir progeny.
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histologically, but not cells expressing hepatocyte
proteins. This proliferation is most likely for bile-duct-
determined stem cells at the stage of differentiation
past that ofthe common stem cell for hepatocytes and
duct cells, perhaps the terminal duct cell. On the other
hand, the oval cells that appear after carcinogen expo-
sure share bile duct and hepatocyte phenotypes
(50,75,76). Thus, there appear to be two distinct types
of ductlike cell proliferation (80): one is nonmalignant
proliferation of bile ducts, the other proliferation of
duct-like oval cells that have the potential to produce
malignant tumors in the liver cell lineage.
Liver Stem Cell and Restitutive
Proliferation
One of the properties of determined stem cells is to
restore amputated or damaged tissue. For example,
the stem cell for the limb of the amphibian is able to
regenerate to form a normal limb after amputation,
but it cannot form other organs (81). The presence ofa
liver stem cell has been questioned in the past because
it did not appear that a liver stem cell was required for
regeneration ofthe liver (Fig. 2). After PH or chemical
injury (CCl4, galactosamine) the liver deficit is
replaced by proliferating hepatocytes that are derived
from adult hepatocytes (82-86). For example, after
two-third PH of the rat, each hepatocyte in the
remaining lobes divides once or twice within a 48-hr
period, without involvement of a stem cell (83,84,
86,87). In fact, AFP can be identified in large, dividing
hepatocytes after PH in the rat (88) and adjacent to
zones of liver injury after CCl4 injury in the mouse
(59).
However, with more severe liver injury, a liver stem
cell may be called upon to restore the liver. For exam-
ple, after severe injury with CCl4, Engelhardt et al (89)
found some small ovallike cells contained AFP, a mark-
er for proliferation, and Petropoulos et al. (90) report-
ed finding mRNA for AFP in small, nonparenchymal
cells. Tournier et al. (91) found large amounts of AFP
and mRNA for AFP after galactosamine injury in pro-
liferating oval cells. Oval-like cells may be seen in
human livers that have been removed after transplan-
tation when the donor liver has suffered too much
damage to restore normal function (J. Demetris, per-
sonal communication).
Stem Cells in Developing Liver
Determined stem cells are also the precursors for
normal adult cells in developing organs (13). In the
liver ofthe developing rat fetus, cells have been identi-
fied that have the characteristics ofthe oval cells seen
in the adult (53,58,88,92-94). At days 12-14 of develop-
ment, there are bipotential precursor epithelial cells
that are capable of differentiation into hepatocytes or
biliary epithelial cells (95-97). The ability to induce
pancreatic duct cells to differentiate into liver cells
(98-100) and for liver cells to differentiate into acini of
cells containing zymogen granules (101) indicates that
there is a common stem cell for liver, biliary ducts, and
pancreas. Thus, there appears to be a determined stem
cell in the fetus that gives rise to pancreas and liver.
Role ofStem Cells in Normal Liver Cell
Turnover
There is some evidence that the cells that make up
the hepatic cords are replaced by proliferating cells
that originate in the portal area and migrate to the cen-
tral zone, where they terminally differentiate and are
removed by apoptosis (102-104). It is proposed that the
heptocytes are formed at the periportal tract rim,
where determined stem cells interact with ductal and
stromal elements. The assembled unit then streams
across the three acinar zones until it reaches the termi-
nal hepatic vein where it is eliminated. The liver unit
replaces itself in a manner similar to, but much slower
than, the layered epithelium ofthe skin or bladder and
the gastrointestinal tract (Fig. 8). In the skin, stem
cells located in the basal layer ofskin divide to produce
daughter cells, one ofwhich differentiates and migrates
to the next layer and eventually terminally differenti-
ates into a non-nucleated squamous cell (28,105,106). A
steady number of gastrointestinal lining cells is main-
tained by a balance of cells proliferating in the lower
levels of the epithelium to those differentiating in the
mid-level ofthe epithelium and exfoliated at the surface
(107,108). A crypt of the small intestine contains 4-16
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FIGURE 8. Comparison of cell renewal in intestine, skin, and liver
proliferons. Normal cell turnover in the gastrointestinal tract,
skin, and liver appears to proceed similarly, but at greatly differ-
ent rates. The small arrows and asterisks denote the location of
proliferating stem cells. Proliferating cells may be demonstrated
in crypts of the gastrointestinal tract up to the opening of the
crypt, limited to the basal layer ofthe skin, and rarely in the liver.
Toxic or destructive events may increase the proliferation rate in
these organs so that proliferating cells may be seen in higher lay-
ers in the skin and in the hepatic cords. Induction of proliferation
of hepatic stem cells requires either massive loss of hepatocytes
or inhibition of hepatocyte proliferation by a necrotic dose of
genotoxic carcinogen.
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actual stem cells in steady state, but up to 30-40 poten-
tial stem cells that maybe activated to divide afterper-
turbations that stimulate proliferation. In man, approx-
imately 1011 epithelial cells are shed every day in the
small intestine (107). It is estimated that the skin
replaces itself every 15-16 days (Jean London, televi-
sion commercial) whereas the liver may take over a
year (83). The number of potential stem cells in the
liver that may be activated has not been estimated;
oval cells most likely represent progeny of activated
stem cells. The characteristic of liver tumors may be
related to the stage of differentiation at which the
malignant phenotype is manifested (Fig. 9), as is postu-
lated forteratocarcinomas and othercancers.
Chemical Hepatocarcinogenesis
and Liver Stem Cells
Cohen and Ellwein (108) have recently emphasized
the role of cell proliferation in the induction of cancer
by chemicals. In considering the principle that two or
more mutations must take place before the malignant
phenotype is expressed (109,110), the role ofchemicals
ATY
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STEM CELL TRANSITION
DUCT CELL
HEPATOBtASTOMA
in inducing HCC may be either to induce a mutation
(genotoxic) or to stimulate proliferation (nongenotox-
ic), allowing internal or spontaneous mutations to take
place. In this explanation initiators induce alterations
in DNA and promoters stimulate proliferation of the
initiated cells, increasing the likelihood for additional
mutations to take place (108). Both promoters and
"endogenous carcinogens" (111) stimulate cell prolifer-
ation and decrease the time that it takes to produce
cancers. Endogenous carcinogens are essentially hor-
mones that stimulate cell proliferation.
Lasting Effect ofInitiation
One ofthe principles ofinitiation is that once a geno-
toxic event occurs, it will persist essentially for the
lifetime ofthe animal (112,113). In skin carcinogenesis,
it must be the stem cell that is mutated. Mutations
that occur in cells that have begun the differentiation
process will not develop into cancer because differenti-
ated cells are committed to terminal differentiation
and eventual death (107,108). This must be true for
skin and gastrointestinal and other epithelial cancers,
as the rapid turnover ofthese cells would remove call
(PICAL HYPERPLASIA
HEPATOCELLULAR
CARCINOMA
HEPATOCYTES
BILE DUCTS
COMBINED HEPATO-
CHOLANGIOCARCINOMA
CHOLANGIOFIBROSIS
C CC
CHOLANGIOCARCINOMA
FIGURE 9. Postulated levels ofexpression ofcarcinogenic events duringhepatocarcinogenesis. The stem cell model ofhepatocarcinogenesis pos-
tulates that carcinogenic events occur in proliferating cells at some stage during differentiation, resulting in expression of the malignant
phenotype (blocked ontogeny). Because carcinogenesis most likely results from the accumulation ofmore than one mutation, it is likely that
the first mutation (initiation) takes place at the level of the stem cell and that later mutations occurring at the level of the transition duct
cells or in aberrantly differentiating cells (atypical hyperplasia or cholangiofibrosis) direct the level of expression of malignancy.
Hepatoblastoma may represent tumors that arise because of multiple mutations at the stem cell level. Tumors with combined features of
hepatocytes and bile ducts (hepatocholangiocarcinomas) may arise from multiple mutations at a later stage ofdifferentiation. Hepatocellular
carcinomas arise from a still later stage ofdifferentiation.
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Table 3.
Effect ofexpression ofhepatitus B virus (HBV) proteins in transgenic mice.
Transgene Promoter Effect Reference
PSX Albumin Necrosis, hepatoma (124-126)
PSX Metallothionein Necrosis, hepatoma (124,126)
PSX HBV PrS No necrosis orfoci, hepatoma (127)
HBx HBxtransgene, enhancer Foci, no necrosis, hepatoma (128)
HBx a-1-antitrypsin Focal necrosis, no hepatoma (129)
cells that have started the differentiation process with-
in 2-5 days for gastrointestinal epithelium, 15-30 days
for skin, and 50 days for pancreas (114). Although the
cellular turnover in the liver is much slower (up to 1
year), it is likely that the same principle holds for liver
cancer. It has been reported that the alterations
induced by chemical hepatocarcinogens may also per-
sist for long periods oftime (115-117). For example, in
unpublished experiments of Becker (personal commu-
nication), administration of phenobarbital as late as 1
year after injection of a non-necrotic dose of DEN (50
mg/kg), which by itself does not cause tumors, gave
rise to primary HCC within 6 months. However,
because ofthe long cellular turnover time in the liver,
it is possible that a partially differentiated cell with the
potential to proliferate might give rise to cancer after
chemical initiation, thus fulfilling the maturation-
arrest postulate ofthe differentiation theory of cancer
(Fig. 2).
Hepatitis B, Hepatocellular
Proliferation, and Hepatocellular
Carcinoma
The incidence of cancer in different organs is closely
related to the rate ofcell turnover (118). The incidence
ofcancer ofthe skin and gastrointestinal tract is much
higher than that of the liver in the western world.
However, in areas of the world where hepatitis B is
endemic and infected individuals have a marked
increased turnover of liver cells related to liver dam-
age, HCC is the most common cancer (119,120). The
association ofa higher incidence ofHCC with hepatitis
B infection is most likely related to the increased
turnover ofliver cells secondary to destruction ofliver
cells, leading to stimulation of proliferation of stem
cells and other cells early in the liver acinus dediffer-
entiation proliferation (121). Similarly, increased resti-
tutive proliferation in cirrhosis is also associated with
increased incidence of HCC (111,123). This increased
liver cell turnover increased the likelihood of endoge-
nous carcinogenesis because of the increased chance
for mutations (108). In transgenic mice expressing
hepatitis B viral (HBV) proteins, liver cancer has
developed both with and without preceding liver cell
damage (124-130; Table 3). In addition, in transgenic
mice that express hepatitis B surface antigen (HBsAg)
and show progressive liver cell proliferation preceding
cancer, exposure to chemical carcinogens such as DEN
or aflatoxin results in HCC at a younger age (131).
Thus, chemical hepatocarcinogens or insertion of HBV
DNA at critical sites (132-135) may provide one muta-
tional event necessary, but not sufficient, to cause
malignant transformation. The increased proliferation
of liver cells induced by cell injury or mitogens (pro-
moters) allows accumulation of the other mutations
required for expression ofthe malignant phenotype.
Relationship ofCarcinogenic Stimulus
to Proliferation ofStem Cells
Regardless of the cause of cancer, the carcinogenic
process includes proliferation of stem cells or their
determined progeny (13,28,136). Thus transforming
viruses, genotoxic chemicals, nongenotoxic chemicals,
tissue injury and repair, and developmental abnormali-
ties that lead to cancer all induce proliferation of tis-
sues requiring the participation of stem cells. In the
case ofteratocarcinomas, it is multipotent stem cell. In
the case of cancer of different tissues, it is the tissue
determined stem cell. It is possible that all cancers
arise from some form of maturation arrest of stem
cells. However, nature usually has more than one way
to get to the same place. Both maturation arrest of
determined stem cells and dedifferentiation of mature
cells may be cellular pathways to cancer.
Portions of this paper are being published in the International
Journal of Developmental Biology. I thank G. Barry Pierce for his
insights into cancer as a problem of developmental biology and for
his continuing moral support.
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